The MEA xenotransplantation market size was accounted for USD 220 million in 2025 and is predicted to touch around USD 597.1 million by 2035, growing at a CAGR of 10.50% from 2026 to 2035. The Middle East region is facing severe human donor organ shortages and witnessing the rising government programs to increase clinical awareness.

MEA Xenotransplantation Market Statical Scope

The regional industrial growth is driven by structural healthcare transformation, regulatory frameworks, and cross-border state programs. Middle Eastern governments have focused on biomanufacturing, foundational infrastructure, and cross-border distribution channels.

The core government initiatives and program launches include the Saudi National Kidney Exchange Program, the UAE-Saudi Cross-Border Organ Transport Framework, and the UAE ‘Heart in a Box' and perfusion pipeline. The operational framework built a logistical system to onboard and distribute bioengineered and xenotransplantation organs at a national level.

MEA Xenotransplantation Market Share, By Type, 2025 (%)

• Transplant Diagnostics - The transplant diagnostics segment dominated the market in 2025, with a share of 38%, owing to advanced genomic sequencing and high-resolution HLA typing. The crucial diagnostic technologies are molecular assays, next-generation sequencing , cell-free DNA, and biomarkers.
• Organ Preservation Solutions - The organ preservation solutions segment held a 34% share and is expected to grow in the coming years, driven by the leading market competitors providing chemical solutions and perfusion technology. They also offer organ recovery systems, preservation solutions, etc.
• Tissue Products - The tissue products segment held a 28% share and is expected to grow in the upcoming period due to the utilization of multiplex CRISPR systems by companies to engineer donor animals with up to 69 genetic modifications. The leading tissue product categories are ocular and corneal tissues, dermal grafts, wound care, cardiovascular, and structural tissues.

MEA Xenotransplantation Market Share, By Application, 2025 (%)

• Kidney - The kidney segment dominated the market in 2025, with a share of 44%, supported by the integral role of biotechnology in transforming highly accessible medical intervention. Xenotransplantation holds the promise of unlimited organ supply, reduced waiting times on national transplant lists, and reduced reliance on dialysis.
• Heart - The heart segment held a 36% share and is expected to grow in the coming years, driven by medical and anatomical benefits such as anatomical compatibility, pathogen control, and genetic customization. Heart xenotransplantation offers operational efficiency in terms of patient pre-treatment, proactive scheduling, and minimal ischemia.
• Other Organs - The other organs segment held a 20% share and is expected to grow in the upcoming period due to potential treatments for organs like the pancreas, intestine, liver, lung, etc., and cellular and tissue therapies for brain cells, pancreatic islets, corneas, and more. The broad benefits across all organs are the elimination of brain death deterioration, expanded patient eligibility, etc.

Competitive Landscape

The regional companies in regenerative medicine and the stem cell sector are CellSave Arabia, Middle East Gene Therapy Company, and Abu Dhabi Stem Cells Center. The CellSave Arabia is the first private stem cell laboratory in the GCC region, which is renowned for the collection, processing, and cryogenic storage of newborn stem cells. Apart from this, the leading international companies in the Middle East are United Therapeutics Corporation, eGenesis, and Novartis AG. They are expanding clinical trials and organ production initiatives globally.

Recent Developments in the MEA Xenotransplantation Market

• In April 2025, Tonix and Makana made a partnership on xenotransplantation research and development. They aim to produce data supporting an investigational new drug application with the U.S. FDA.

Segments Covered in the Report

By Type

• Organ Preservation Solutions
• Transplant Diagnostics
• Tissue Products

By Application

• Heart
• Kidney
• Other Organs